Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated:  1/10/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated: 1/10/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated:  1/10/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated: 1/10/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated:  1/10/2017
Weill-Cornell Medical College
mi
from
New York, NY
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated: 1/10/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated:  1/10/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated: 1/10/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated:  1/10/2017
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated: 1/10/2017
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated:  1/10/2017
Geisinger Cancer Center
mi
from
Danville, PA
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated: 1/10/2017
Geisinger Cancer Center
mi
from
Danville, PA
Click here to add this to my saved trials
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated:  1/10/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated: 1/10/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated:  1/10/2017
University of Utah
mi
from
Salt Lake City, UT
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated: 1/10/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated:  1/10/2017
Ospedale Riuniti de Bergamo
mi
from
Bergamo,
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Status: Enrolling
Updated: 1/10/2017
Ospedale Riuniti de Bergamo
mi
from
Bergamo,
Click here to add this to my saved trials
Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
A Phase 1 Escalating Dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
A Phase 1 Escalating Dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
A Multi-centre, Randomised, Double-blind, Parallel Groups, Placebocontrolled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Treatment of Bleeding in Patients Following Stem Cell Transplantation (SCT)
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Chapel Hill, NC
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
A Multi-centre, Randomised, Double-blind, Parallel Groups, Placebocontrolled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Treatment of Bleeding in Patients Following Stem Cell Transplantation (SCT)
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
A Multi-centre, Randomised, Double-blind, Parallel Groups, Placebocontrolled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Treatment of Bleeding in Patients Following Stem Cell Transplantation (SCT)
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Herston,
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
A Multi-centre, Randomised, Double-blind, Parallel Groups, Placebocontrolled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Treatment of Bleeding in Patients Following Stem Cell Transplantation (SCT)
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Herston,
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Tucson, AZ
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
San Francisco, CA
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Denver, CO
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Indianapolis, IN
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Camden, NJ
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Camden, NJ
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Bronx, NY
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
New York, NY
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Cleveland, OH
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Portland, OR
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Allentown, PA
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Allentown, PA
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Houston, TX
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Richmond, VA
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated:  1/10/2017
Novo Nordisk Investigational Site
mi
from
Toronto,
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status: Enrolling
Updated: 1/10/2017
Novo Nordisk Investigational Site
mi
from
Toronto,
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Little Rock, AR
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Berkeley, CA
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Berkeley, CA
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Aurora, CO
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Chicago, IL
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Indianapolis, IN
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
New Orleans, LA
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Boston, MA
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Detroit, MI
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Minneapolis, MN
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
New Brunswick, NJ
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Newark, NJ
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Newark, NJ
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
New York, NY
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Chapel Hill, NC
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Cincinnati, OH
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Hershey, PA
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Hershey, PA
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Houston, TX
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Response to Recombinant Factor VIIa When Administered for Bleed
Recombinant Activated Factor VII (rFVIIa/NovoSeven) Dose Response Trial in Healthy Volunteers: A Double-Blind, Placebo-Controlled, Cross-over, Dose-Escalation Trial to Investigate the Dose Response to REcombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy Volunteers
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Overland Park, KA
Dose Response to Recombinant Factor VIIa When Administered for Bleed
Recombinant Activated Factor VII (rFVIIa/NovoSeven) Dose Response Trial in Healthy Volunteers: A Double-Blind, Placebo-Controlled, Cross-over, Dose-Escalation Trial to Investigate the Dose Response to REcombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy Volunteers
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Berkeley, CA
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Berkeley, CA
Click here to add this to my saved trials
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Chicago, IL
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Indianapolis, IN
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials